Ginseng and ginsenosides on cardiovascular and pulmonary diseases; Pharmacological potentials for the coronavirus...

Area of Science:

• Biochemistry
• Pharmacology
• Immunology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, has led to significant global mortality and morbidity.
• Cardiovascular and pulmonary complications are major concerns in severe COVID-19 cases.
• Delayed detection of disease biomarkers and viral replication pathways contribute to mortality.

Purpose of the Study:

• To review the therapeutic potential of ginseng and ginsenosides in managing COVID-19.
• To explore their role in suppressing key biomarkers and downregulating critical cellular pathways.
• To assess their efficacy in mitigating cardiovascular and pulmonary damage.

Main Methods:

• Literature review of studies on ginseng, ginsenosides, and COVID-19.
• Analysis of ginseng's impact on biomarkers like C-reactive protein, troponin, and creatine kinase.
• Examination of ginseng's effect on cellular signaling pathways (e.g., Renin-angiotensin system, MAPK, PI3K).

Main Results:

• Ginseng and ginsenosides have demonstrated the ability to suppress elevated biomarkers associated with COVID-19 severity.
• These compounds can downregulate key cellular pathways involved in SARS-CoV-2 replication and inflammation.
• Evidence suggests therapeutic potential in alleviating cardiac and pulmonary damage.

Conclusions:

• Ginseng and ginsenosides offer a promising natural approach to controlling COVID-19-related cardiovascular and pulmonary complications.
• Supplementation may reduce biomarker levels and mitigate disease progression.
• Further research supports ginseng's role in managing viral infections and their sequelae.